APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drug Stability Testing

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drug Stability Testing Market Outlook and Growth Opportunities 2026

11 April 2026Not stated

Choose your research edition.

Industry ResearchDrug Stability Testing Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Drug Stability Testing Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Drug Stability Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drug Stability Testing Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Drug Stability Testing Market Analysis and Forecast 2026-2032233 pages · $4,950 USD

Market perspective

The global Drug Stability Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drug Stability Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drug Stability Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drug Stability Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drug Stability Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drug Stability Testing market include Q Laboratories, Eurofins BioPharma, Intertek Group, Labcorp, Charles River Laboratories, SGS, Pacific BioLabs, Element Materials Technology and Catalent, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Drug Stability Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drug Stability Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drug Stability Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drug Stability Testing market.

Drug Stability Testing Segment by Company

Q Laboratories

Eurofins BioPharma

Intertek Group

Labcorp

Charles River Laboratories

SGS

Pacific BioLabs

Element Materials Technology

Catalent

Nelson Labs

PerkinElmer

BioProcess International

Ardena

Selvita

Alcami

Drug Stability Testing Segment by Type

Drug Substances

Finished Drug

Drug Stability Testing Segment by Application

Pharmaceutical Companies

Biopharmaceutical and Vaccine Companies

Advanced Therapies Companies

Others

Drug Stability Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drug Stability Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drug Stability Testing key companies, revenue, market share, and recent developments.

3. To split the Drug Stability Testing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drug Stability Testing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drug Stability Testing significant trends, drivers, influence factors in global and regions.

6. To analyze Drug Stability Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Stability Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drug Stability Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Stability Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drug Stability Testing industry.

Chapter 3: Detailed analysis of Drug Stability Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drug Stability Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drug Stability Testing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drug Stability Testing Industry Trends Table 2. Drug Stability Testing Industry Drivers Table 3. Drug Stability Testing Industry Opportunities and Challenges Table 4. Drug Stability Testing Industry Restraints Table 5. Global Drug Stability Testing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drug Stability Testing Revenue Share by Company (2021-2026) Table 7. Global Drug Stability Testing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drug Stability Testing Key Company Manufacturing Base & Headquarters Table 9. Global Drug Stability Testing Company, Product Type & Application Table 10. Global Drug Stability Testing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drug Stability Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Drug Substances Table 15. Significant Companies of Finished Drug Table 16. Global Drug Stability Testing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Drug Stability Testing Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Drug Stability Testing Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Drug Stability Testing Sales Value Share by Type (2021-2026) Table 20. Global Drug Stability Testing Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Pharmaceutical Companies Table 22. Significant Companies of Biopharmaceutical and Vaccine Companies Table 23. Significant Companies of Advanced Therapies Companies Table 24. Significant Companies of Others Table 25. Global Drug Stability Testing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Drug Stability Testing Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Drug Stability Testing Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Drug Stability Testing Sales Value Share by Application (2021-2026) Table 29. Global Drug Stability Testing Sales Value Share by Application (2027-2032) Table 30. Global Drug Stability Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Drug Stability Testing Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Drug Stability Testing Sales Value Share by Region (2021-2026) Table 33. Global Drug Stability Testing Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Drug Stability Testing Sales Value Share by Region (2027-2032) Table 35. Global Drug Stability Testing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Drug Stability Testing Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Drug Stability Testing Sales Value Market Share by Country (2021-2026) Table 38. Global Drug Stability Testing Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Drug Stability Testing Sales Value Market Share by Country (2027-2032) Table 40. Q Laboratories Company Information Table 41. Q Laboratories Business Overview Table 42. Q Laboratories Drug Stability Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Q Laboratories Drug Stability Testing Product Portfolio Table 44. Q Laboratories Recent Development Table 45. Eurofins BioPharma Company Information Table 46. Eurofins BioPharma Business Overview Table 47. Eurofins BioPharma Drug Stability Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Eurofins BioPharma Drug Stability Testing Product Portfolio Table 49. Eurofins BioPharma Recent Development Table 50. Intertek Group Company Information Table 51. Intertek Group Business Overview Table 52. Intertek Group Drug Stability Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Intertek Group Drug Stability Testing Product Portfolio Table 54. Intertek Group Recent Development Table 55. Labcorp Company Information Table 56. Labcorp Business Overview Table 57. Labcorp Drug Stability Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Labcorp Drug Stability Testing Product Portfolio Table 59. Labcorp Recent Development Table 60. Charles River Laboratories Company Information Table 61. Charles River Laboratories Business Overview Table 62. Charles River Laboratories Drug Stability Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Charles River Laboratories Drug Stability Testing Product Portfolio Table 64. Charles River Laboratories Recent Development Table 65. SGS Company Information Table 66. SGS Business Overview Table 67. SGS Drug Stability Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. SGS Drug Stability Testing Product Portfolio Table 69. SGS Recent Development Table 70. Pacific BioLabs Company Information Table 71. Pacific BioLabs Business Overview Table 72. Pacific BioLabs Drug Stability Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Pacific BioLabs Drug Stability Testing Product Portfolio Table 74. Pacific BioLabs Recent Development Table 75. Element Materials Technology Company Information Table 76. Element Materials Technology Business Overview Table 77. Element Materials Technology Drug Stability Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Element Materials Technology Drug Stability Testing Product Portfolio Table 79. Element Materials Technology Recent Development Table 80. Catalent Company Information Table 81. Catalent Business Overview Table 82. Catalent Drug Stability Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Catalent Drug Stability Testing Product Portfolio Table 84. Catalent Recent Development Table 85. Nelson Labs Company Information Table 86. Nelson Labs Business Overview Table 87. Nelson Labs Drug Stability Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Nelson Labs Drug Stability Testing Product Portfolio Table 89. Nelson Labs Recent Development Table 90. PerkinElmer Company Information Table 91. PerkinElmer Business Overview Table 92. PerkinElmer Drug Stability Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. PerkinElmer Drug Stability Testing Product Portfolio Table 94. PerkinElmer Recent Development Table 95. BioProcess International Company Information Table 96. BioProcess International Business Overview Table 97. BioProcess International Drug Stability Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. BioProcess International Drug Stability Testing Product Portfolio Table 99. BioProcess International Recent Development Table 100. Ardena Company Information Table 101. Ardena Business Overview Table 102. Ardena Drug Stability Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Ardena Drug Stability Testing Product Portfolio Table 104. Ardena Recent Development Table 105. Selvita Company Information Table 106. Selvita Business Overview Table 107. Selvita Drug Stability Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Selvita Drug Stability Testing Product Portfolio Table 109. Selvita Recent Development Table 110. Alcami Company Information Table 111. Alcami Business Overview Table 112. Alcami Drug Stability Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Alcami Drug Stability Testing Product Portfolio Table 114. Alcami Recent Development Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Drug Stability Testing Product Image Figure 2. Global Drug Stability Testing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drug Stability Testing Market Size (2021-2032) & (US$ Million) Figure 4. Global Drug Stability Testing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Drug Substances Image Figure 8. Finished Drug Image Figure 9. Global Drug Stability Testing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Drug Stability Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Drug Stability Testing Sales Value Share by Type (2021-2032) Figure 12. Pharmaceutical Companies Image Figure 13. Biopharmaceutical and Vaccine Companies Image Figure 14. Advanced Therapies Companies Image Figure 15. Others Image Figure 16. Global Drug Stability Testing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Drug Stability Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Drug Stability Testing Sales Value Share by Application (2021-2032) Figure 19. Global Drug Stability Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Drug Stability Testing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Drug Stability Testing Sales Value (2021-2032) & (US$ Million) Figure 22. North America Drug Stability Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Drug Stability Testing Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Drug Stability Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Drug Stability Testing Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Drug Stability Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Drug Stability Testing Sales Value (2021-2032) & (US$ Million) Figure 28. South America Drug Stability Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Drug Stability Testing Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Drug Stability Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Drug Stability Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Drug Stability Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Drug Stability Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Drug Substances
  • Finished Drug
Applications
  • Pharmaceutical Companies
  • Biopharmaceutical and Vaccine Companies
  • Advanced Therapies Companies
  • Others
Companies covered
  • Q Laboratories
  • Eurofins BioPharma
  • Intertek Group
  • Labcorp
  • Charles River Laboratories
  • SGS
  • Pacific BioLabs
  • Element Materials Technology
  • Catalent
  • Nelson Labs
  • PerkinElmer
  • BioProcess International
  • Ardena
  • Selvita
  • Alcami

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drug Stability Testing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drug Stability Testing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drug Stability Testing Market Dynamics
  1. 2.1 Drug Stability Testing Industry Trends
  2. 2.2 Drug Stability Testing Industry Drivers
  3. 2.3 Drug Stability Testing Industry Opportunities and Challenges
  4. 2.4 Drug Stability Testing Industry Restraints
3 Drug Stability Testing Market by Company
  1. 3.1 Global Drug Stability Testing Company Revenue Ranking in 2025
  2. 3.2 Global Drug Stability Testing Revenue by Company (2021-2026)
  3. 3.3 Global Drug Stability Testing Company Ranking (2024-2026)
  4. 3.4 Global Drug Stability Testing Company Manufacturing Base and Headquarters
  5. 3.5 Global Drug Stability Testing Company Product Type and Application
  6. 3.6 Global Drug Stability Testing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drug Stability Testing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drug Stability Testing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drug Stability Testing Market by Type
  1. 4.1 Drug Stability Testing Type Introduction
  2. 4.1.1 Drug Substances
  3. 4.1.2 Finished Drug
  4. 4.2 Global Drug Stability Testing Sales Value by Type
  5. 4.2.1 Global Drug Stability Testing Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Drug Stability Testing Sales Value by Type (2021-2032)
  7. 4.2.3 Global Drug Stability Testing Sales Value Share by Type (2021-2032)
5 Drug Stability Testing Market by Application
  1. 5.1 Drug Stability Testing Application Introduction
  2. 5.1.1 Pharmaceutical Companies
  3. 5.1.2 Biopharmaceutical and Vaccine Companies
  4. 5.1.3 Advanced Therapies Companies
  5. 5.1.4 Others
  6. 5.2 Global Drug Stability Testing Sales Value by Application
  7. 5.2.1 Global Drug Stability Testing Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Drug Stability Testing Sales Value by Application (2021-2032)
  9. 5.2.3 Global Drug Stability Testing Sales Value Share by Application (2021-2032)
6 Drug Stability Testing Regional Value Analysis
  1. 6.1 Global Drug Stability Testing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drug Stability Testing Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drug Stability Testing Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drug Stability Testing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drug Stability Testing Sales Value (2021-2032)
  7. 6.3.2 North America Drug Stability Testing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drug Stability Testing Sales Value (2021-2032)
  10. 6.4.2 Europe Drug Stability Testing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drug Stability Testing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drug Stability Testing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drug Stability Testing Sales Value (2021-2032)
  16. 6.6.2 South America Drug Stability Testing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drug Stability Testing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drug Stability Testing Sales Value Share by Country, 2025 VS 2032
7 Drug Stability Testing Country-level Value Analysis
  1. 7.1 Global Drug Stability Testing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drug Stability Testing Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drug Stability Testing Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drug Stability Testing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drug Stability Testing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drug Stability Testing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drug Stability Testing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drug Stability Testing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drug Stability Testing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drug Stability Testing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drug Stability Testing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drug Stability Testing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drug Stability Testing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drug Stability Testing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drug Stability Testing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drug Stability Testing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drug Stability Testing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drug Stability Testing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drug Stability Testing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drug Stability Testing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drug Stability Testing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drug Stability Testing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drug Stability Testing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drug Stability Testing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drug Stability Testing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drug Stability Testing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drug Stability Testing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drug Stability Testing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drug Stability Testing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drug Stability Testing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drug Stability Testing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drug Stability Testing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drug Stability Testing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drug Stability Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Q Laboratories
  2. 8.1.1 Q Laboratories Company Information
  3. 8.1.2 Q Laboratories Business Overview
  4. 8.1.3 Q Laboratories Drug Stability Testing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Q Laboratories Drug Stability Testing Product Portfolio
  6. 8.1.5 Q Laboratories Recent Developments
  7. 8.2 Eurofins BioPharma
  8. 8.2.1 Eurofins BioPharma Company Information
  9. 8.2.2 Eurofins BioPharma Business Overview
  10. 8.2.3 Eurofins BioPharma Drug Stability Testing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eurofins BioPharma Drug Stability Testing Product Portfolio
  12. 8.2.5 Eurofins BioPharma Recent Developments
  13. 8.3 Intertek Group
  14. 8.3.1 Intertek Group Company Information
  15. 8.3.2 Intertek Group Business Overview
  16. 8.3.3 Intertek Group Drug Stability Testing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Intertek Group Drug Stability Testing Product Portfolio
  18. 8.3.5 Intertek Group Recent Developments
  19. 8.4 Labcorp
  20. 8.4.1 Labcorp Company Information
  21. 8.4.2 Labcorp Business Overview
  22. 8.4.3 Labcorp Drug Stability Testing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Labcorp Drug Stability Testing Product Portfolio
  24. 8.4.5 Labcorp Recent Developments
  25. 8.5 Charles River Laboratories
  26. 8.5.1 Charles River Laboratories Company Information
  27. 8.5.2 Charles River Laboratories Business Overview
  28. 8.5.3 Charles River Laboratories Drug Stability Testing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Charles River Laboratories Drug Stability Testing Product Portfolio
  30. 8.5.5 Charles River Laboratories Recent Developments
  31. 8.6 SGS
  32. 8.6.1 SGS Company Information
  33. 8.6.2 SGS Business Overview
  34. 8.6.3 SGS Drug Stability Testing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 SGS Drug Stability Testing Product Portfolio
  36. 8.6.5 SGS Recent Developments
  37. 8.7 Pacific BioLabs
  38. 8.7.1 Pacific BioLabs Company Information
  39. 8.7.2 Pacific BioLabs Business Overview
  40. 8.7.3 Pacific BioLabs Drug Stability Testing Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pacific BioLabs Drug Stability Testing Product Portfolio
  42. 8.7.5 Pacific BioLabs Recent Developments
  43. 8.8 Element Materials Technology
  44. 8.8.1 Element Materials Technology Company Information
  45. 8.8.2 Element Materials Technology Business Overview
  46. 8.8.3 Element Materials Technology Drug Stability Testing Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Element Materials Technology Drug Stability Testing Product Portfolio
  48. 8.8.5 Element Materials Technology Recent Developments
  49. 8.9 Catalent
  50. 8.9.1 Catalent Company Information
  51. 8.9.2 Catalent Business Overview
  52. 8.9.3 Catalent Drug Stability Testing Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Catalent Drug Stability Testing Product Portfolio
  54. 8.9.5 Catalent Recent Developments
  55. 8.10 Nelson Labs
  56. 8.10.1 Nelson Labs Company Information
  57. 8.10.2 Nelson Labs Business Overview
  58. 8.10.3 Nelson Labs Drug Stability Testing Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Nelson Labs Drug Stability Testing Product Portfolio
  60. 8.10.5 Nelson Labs Recent Developments
  61. 8.11 PerkinElmer
  62. 8.11.1 PerkinElmer Company Information
  63. 8.11.2 PerkinElmer Business Overview
  64. 8.11.3 PerkinElmer Drug Stability Testing Revenue and Gross Margin (2021-2026)
  65. 8.11.4 PerkinElmer Drug Stability Testing Product Portfolio
  66. 8.11.5 PerkinElmer Recent Developments
  67. 8.12 BioProcess International
  68. 8.12.1 BioProcess International Company Information
  69. 8.12.2 BioProcess International Business Overview
  70. 8.12.3 BioProcess International Drug Stability Testing Revenue and Gross Margin (2021-2026)
  71. 8.12.4 BioProcess International Drug Stability Testing Product Portfolio
  72. 8.12.5 BioProcess International Recent Developments
  73. 8.13 Ardena
  74. 8.13.1 Ardena Company Information
  75. 8.13.2 Ardena Business Overview
  76. 8.13.3 Ardena Drug Stability Testing Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Ardena Drug Stability Testing Product Portfolio
  78. 8.13.5 Ardena Recent Developments
  79. 8.14 Selvita
  80. 8.14.1 Selvita Company Information
  81. 8.14.2 Selvita Business Overview
  82. 8.14.3 Selvita Drug Stability Testing Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Selvita Drug Stability Testing Product Portfolio
  84. 8.14.5 Selvita Recent Developments
  85. 8.15 Alcami
  86. 8.15.1 Alcami Company Information
  87. 8.15.2 Alcami Business Overview
  88. 8.15.3 Alcami Drug Stability Testing Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Alcami Drug Stability Testing Product Portfolio
  90. 8.15.5 Alcami Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst